S&P 500   5,005.77 (-0.11%)
DOW   37,986.71 (+0.56%)
QQQ   419.10 (-1.02%)
AAPL   165.24 (-1.08%)
MSFT   400.87 (-0.84%)
META   486.86 (-2.98%)
GOOGL   154.62 (-0.89%)
AMZN   176.16 (-1.71%)
TSLA   149.13 (-0.53%)
NVDA   817.73 (-3.42%)
AMD   150.76 (-2.79%)
NIO   3.86 (-3.50%)
BABA   68.70 (-0.26%)
T   16.39 (+0.37%)
F   12.09 (+0.25%)
MU   109.05 (-2.57%)
GE   150.94 (-1.31%)
CGC   7.55 (-3.58%)
DIS   111.91 (-0.46%)
AMC   3.15 (+7.88%)
PFE   25.56 (+0.67%)
PYPL   62.04 (-0.10%)
XOM   120.52 (+1.69%)
S&P 500   5,005.77 (-0.11%)
DOW   37,986.71 (+0.56%)
QQQ   419.10 (-1.02%)
AAPL   165.24 (-1.08%)
MSFT   400.87 (-0.84%)
META   486.86 (-2.98%)
GOOGL   154.62 (-0.89%)
AMZN   176.16 (-1.71%)
TSLA   149.13 (-0.53%)
NVDA   817.73 (-3.42%)
AMD   150.76 (-2.79%)
NIO   3.86 (-3.50%)
BABA   68.70 (-0.26%)
T   16.39 (+0.37%)
F   12.09 (+0.25%)
MU   109.05 (-2.57%)
GE   150.94 (-1.31%)
CGC   7.55 (-3.58%)
DIS   111.91 (-0.46%)
AMC   3.15 (+7.88%)
PFE   25.56 (+0.67%)
PYPL   62.04 (-0.10%)
XOM   120.52 (+1.69%)
S&P 500   5,005.77 (-0.11%)
DOW   37,986.71 (+0.56%)
QQQ   419.10 (-1.02%)
AAPL   165.24 (-1.08%)
MSFT   400.87 (-0.84%)
META   486.86 (-2.98%)
GOOGL   154.62 (-0.89%)
AMZN   176.16 (-1.71%)
TSLA   149.13 (-0.53%)
NVDA   817.73 (-3.42%)
AMD   150.76 (-2.79%)
NIO   3.86 (-3.50%)
BABA   68.70 (-0.26%)
T   16.39 (+0.37%)
F   12.09 (+0.25%)
MU   109.05 (-2.57%)
GE   150.94 (-1.31%)
CGC   7.55 (-3.58%)
DIS   111.91 (-0.46%)
AMC   3.15 (+7.88%)
PFE   25.56 (+0.67%)
PYPL   62.04 (-0.10%)
XOM   120.52 (+1.69%)
S&P 500   5,005.77 (-0.11%)
DOW   37,986.71 (+0.56%)
QQQ   419.10 (-1.02%)
AAPL   165.24 (-1.08%)
MSFT   400.87 (-0.84%)
META   486.86 (-2.98%)
GOOGL   154.62 (-0.89%)
AMZN   176.16 (-1.71%)
TSLA   149.13 (-0.53%)
NVDA   817.73 (-3.42%)
AMD   150.76 (-2.79%)
NIO   3.86 (-3.50%)
BABA   68.70 (-0.26%)
T   16.39 (+0.37%)
F   12.09 (+0.25%)
MU   109.05 (-2.57%)
GE   150.94 (-1.31%)
CGC   7.55 (-3.58%)
DIS   111.91 (-0.46%)
AMC   3.15 (+7.88%)
PFE   25.56 (+0.67%)
PYPL   62.04 (-0.10%)
XOM   120.52 (+1.69%)
OTCMKTS:EMBI

Emerald Bioscience (EMBI) Stock Price, News & Analysis

Today's Range
N/A
50-Day Range
$0.09
$17.75
52-Week Range
N/A
Volume
6.96 million shs
Average Volume
14.24 million shs
Market Capitalization
$24.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
EMBI stock logo

About Emerald Bioscience Stock (OTCMKTS:EMBI)

Emerald Bioscience, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of cannabinoid-based therapeutics for unmet medical needs worldwide. The company's lead product candidate is NB1111, which is in preclinical trials for the treatment of glaucoma. It is also developing NB2222, a product candidate in preclinical trials for use in the treatment of various eye diseases, including uveitis, dry eye syndrome, macular degeneration, and diabetic retinopathy; and NB3111, a cannabinoid cocktail in testing for use as an anti-infective agent against various strains of antibiotic resistant bacteria, including methicillin-resistant Staphylococcus aureus. The company was formerly known as Nemus Bioscience, Inc. and changed its name to Emerald Bioscience, Inc. in March 2019. Emerald Bioscience, Inc. was founded in 2012 and is based in San Diego, California.

EMBI Stock News Headlines

2024's Must-Have Guide: Master Crypto Investment Today
The cryptocurrency revolution is here with Bitcoin soaring past the $70,000 milestone—a clear indicator of the booming digital currency market. Are you prepared to navigate these exciting yet complex waters? Introducing "Navigating the Future: A Comprehensive Guide to Cryptocurrency Investments in 2024." This free digital guide is your essential resource for understanding and capitalizing on cryptocurrency investments, tailored for both newcomers and seasoned investors. (**By clicking the link you are subscribing to The Conservative Investor Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)
Daré Bioscience, Inc. (DARE)
Don’t expose yourself to stocks during the week
The S&P 500 just crossed below the 200 day moving average… The Nasdaq is bleeding out… Are we headed for a recession?! If you’ve been in the stock market the last few months, it hasn’t been fun… But what if I told you there was a way to target “BONUS” income just by doing a unique type of trade over the weekend? When the markets are closed. And volatility is minimal.
See More Headlines
Receive EMBI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Emerald Bioscience and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
N/A
Sub-Industry
N/A
Current Symbol
OTCMKTS:EMBI
CIK
N/A
Fax
N/A
Employees
4
Year Founded
N/A

Profitability

Net Income
$1.05 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Market Cap
$24.13 million
Optionable
Not Optionable
Beta
0.43
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. Punit S. Dhillon B.A. (Age 40)
    BA, Exec. Chairman & CEO
    Comp: $65k
  • Mr. Richard Janney
    Interim Principal Accounting Officer
  • Ms. Elena Traistaru (Age 61)
    Company Sec.

EMBI Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Emerald Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Emerald Bioscience investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), Charlotte's Web (CWBHF), Akero Therapeutics (AKRO), CymaBay Therapeutics (CBAY), Cognex (CGNX), Cumberland Pharmaceuticals (CPIX), Corbus Pharmaceuticals (CRBP) and Editas Medicine (EDIT).

How do I buy shares of Emerald Bioscience?

Shares of EMBI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:EMBI) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners